News
DICE
47.55
0.00%
0.00
Stifel cuts Morphic to hold, doesn't see it as near-term M&A target
Seeking Alpha · 08/09/2023 22:43
Dice Therapeutics, Inc.: [Amend]General statement of acquisition of beneficial ownership
Press release · 08/09/2023 22:16
Dice Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
Press release · 08/09/2023 22:16
*News On DICE Therapeutics Inc. (DICE) Now Under LLY
Dow Jones · 08/09/2023 21:08
What 9 Analyst Ratings Have To Say About DICE Therapeutics
Benzinga · 08/09/2023 20:00
Dice Therapeutics, Inc.: Current report
Press release · 08/09/2023 18:04
Dice Therapeutics, Inc.: Amendments to 40 Act only filings
Press release · 08/09/2023 18:04
Dice Therapeutics, Inc.: Securities to be offered to employees in employee benefit plans, post-effective amendments
Press release · 08/09/2023 18:04
More
Webull provides a variety of real-time DICE stock news. You can receive the latest news about Dice Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DICE
DICE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing oral therapeutics against well-validated targets in immunology. The Company's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The Company's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.